Testosterone And Longevity: What The Evidence Shows
Does testosterone affect lifespan? Review the TRAVERSE trial data, 2024 mortality research, and monitoring guidelines for TRT in men with hypogonadism.
A 2024 meta-analysis of over 24,000 men published in the Annals of Internal Medicine found that testosterone levels below 213 ng/dL were linked to higher all-cause mortality (Yeap et al., 2024). At the same time, animal studies have repeatedly shown that reducing androgen exposure can extend lifespan. These two findings don't contradict each other, but they reveal something most online debates about testosterone and longevity miss: context determines whether testosterone supports health or works against it. It depends on baseline levels, age, comorbidities, and how the hormone is administered.
What Does the Research Say About Low Testosterone and Mortality?
Low testosterone is associated with increased mortality risk, with the strongest signal coming from cardiovascular disease. The Yeap meta-analysis pooled results from 11 prospective studies. Men with total testosterone below 213 ng/dL had elevated all-cause mortality risk. Those below 153 ng/dL faced increased cardiovascular mortality specifically (Yeap et al., 2024).
But correlation isn't causation. Low testosterone often accompanies obesity, type 2 diabetes, and metabolic syndrome. A man with a total testosterone of 180 ng/dL and a BMI of 38 may have low levels because of metabolic dysfunction rather than the reverse. Prostate cancer patients on androgen deprivation therapy also experience increased cardiovascular events (Nguyen et al., 2011), though ADT affects multiple hormonal pathways, making it hard to isolate testosterone as the sole factor.
Elevated luteinizing hormone (above 10 IU/L) also predicted higher mortality, suggesting primary hypogonadism carries its own distinct risk. The number alone doesn't tell the full story without evaluating symptoms, metabolic health, and the underlying cause of the deficiency.
Can Testosterone Therapy Reduce Cardiovascular Risk?
Two early observational studies (Vigen et al., 2013; Finkle et al., 2014) reported increased heart attack risk in men on testosterone, prompting an FDA warning in 2015. Both had serious methodological limitations.
The TRAVERSE trial (an industry-funded study sponsored by AbbVie), published in the New England Journal of Medicine in 2023, enrolled 5,246 men aged 45 to 80 with cardiovascular risk and confirmed hypogonadism. Testosterone gel didn't meet the threshold for increased cardiovascular risk under a non-inferiority design. The hazard ratio was 0.96 (95% CI, 0.78-1.17), though the upper bound means a modest increase couldn't be fully excluded (Lincoff et al., 2023).
Based on these results, the FDA updated testosterone product labeling in February 2025, removing the cardiovascular boxed warning and adding a new warning about blood pressure increases with required monitoring (FDA, 2025). TRAVERSE also identified higher rates of atrial fibrillation and acute kidney injury in the testosterone group. And the trial only studied transdermal gel in men with confirmed deficiency, not supraphysiologic dosing or use in men with normal levels.
Does Higher Testosterone Always Mean a Longer Life?
No. Evolutionary biology consistently shows a trade-off between reproductive investment and lifespan (Kirkwood, 2005). In animal models, castration extends lifespan across multiple species (Hamilton & Mestler, 1969; Drori & Folman, 1976). A small 2012 analysis of Korean eunuchs suggested they lived 14 to 19 years longer than intact males, though the study's reliance on centuries-old genealogical records and small sample of 81 individuals limits the conclusions (Min et al., 2012).
Women live an average of seven years longer than men. This gap reflects genetic, hormonal, behavioral, and social factors. Some researchers attribute part of the hormonal component to the immunosuppressive effects of androgens (Gubbels Bupp et al., 2018).
None of this means extremely low testosterone is desirable. The Yeap mortality data shows the opposite. But it suggests that supraphysiologic levels, the kind seen with steroid abuse, likely carry a biological cost. The goal for men with confirmed deficiency is physiologic replacement, individualized based on symptom response and ongoing monitoring.
What Happens When Testosterone Is Too Low?
Men with clinically low testosterone, confirmed by two early-morning blood draws below 300 ng/dL with associated symptoms, may experience reduced libido, erectile dysfunction, fatigue, muscle loss, increased visceral fat, and depressed mood. The American Urological Association uses a threshold of total testosterone below 300 ng/dL on two separate morning draws to support evaluation for hypogonadism (Mulhall et al., 2018).
These symptoms overlap with sleep apnea, depression, thyroid dysfunction, iron deficiency, and chronic stress. That's why a blood test alone isn't diagnostic. Clinical evaluation should include LH and FSH to distinguish primary from secondary hypogonadism, prolactin to rule out pituitary pathology, and metabolic markers like fasting glucose. Obesity is one of the strongest predictors of low levels, and weight loss alone can raise testosterone by 50 to 100 ng/dL in obese men (Corona et al., 2013). Addressing reversible causes before starting testosterone therapy should be the first step. The decision to treat should involve shared decision-making about benefits, risks, and the patient's goals.
How Does Testosterone Therapy Affect the Body Over Time?
Libido and energy often improve within three to six weeks. Body composition changes become measurable around three to six months. Bone mineral density improvements may take one to three years (Bhasin et al., 2018).
The trade-off: testosterone therapy suppresses the body's own production. LH and FSH drop, testes shrink, and sperm production can fall to zero. For men who want to preserve male fertility, providers may prescribe hCG alongside TRT or recommend alternatives to TRT altogether.
Hematocrit rises on testosterone therapy. Clinical guidelines flag levels above 54% as requiring dose reduction or phlebotomy (Bhasin et al., 2018; Mulhall et al., 2018). A 2025 retrospective study found that 23% of men on TRT reached a hematocrit above 50% (Neidhart et al., 2025). Other risks include acne, fluid retention, mood instability, breast tissue growth, and elevated estradiol from excess testosterone converting to estrogen. These aren't trivial. They're the reason responsible protocols include regular monitoring.
What Monitoring Should Men on TRT Expect?
The Endocrine Society's 2018 guidelines recommend two pre-treatment morning testosterone draws, baseline PSA, hematocrit, lipid panel, and metabolic markers. Blood pressure assessment is now included in FDA-required labeling per the 2025 update.
At three to six months: repeat trough testosterone, hematocrit, PSA, estradiol, and blood pressure. Annually thereafter: full panel repeat. Hematocrit above 54% warrants dose reduction or phlebotomy. Men who skip routine monitoring are at increased risk for preventable complications. Consistent follow-up is what allows the safety profile demonstrated in clinical trials to translate to real-world outcomes.
Can Lifestyle Changes Raise Testosterone Without Medication?
For men with borderline-low levels (200-350 ng/dL) driven by modifiable factors, lifestyle should come first. A 2020 systematic review found resistance training raised total testosterone by 45-55 ng/dL in previously untrained men (Riachy et al., 2020). Weight loss has a bigger effect. A 10% body weight reduction produced testosterone increases of 80-100 ng/dL in obese men (Corona et al., 2022). Sleep deprivation of fewer than five hours per night reduced daytime testosterone by 10-15% in young men (Leproult & Van Cauter, 2011).
Correcting confirmed zinc and vitamin D deficiencies can produce modest improvements. But taking micronutrient supplements when levels are already normal does nothing. Lifestyle interventions also won't restore levels in men with primary hypogonadism or significant pituitary pathology. These men need medical treatment.
Should Men Worry That TRT Will Shorten Their Lifespan?
For men with confirmed hypogonadism, supervised testosterone replacement to physiologic levels hasn't been shown to increase cardiovascular mortality in the best available randomized data. Observational data suggests leaving severely low testosterone untreated may itself carry risk.
For men with normal levels who pursue TRT for performance or cosmetic reasons, there's no randomized trial data supporting safety. Men using supraphysiologic doses face well-documented risks: erythrocytosis, left ventricular hypertrophy, and fertility suppression (Pope et al., 2014).
The most honest framing: physiologic replacement in deficient men, monitored appropriately, hasn't increased major cardiovascular events in roughly two years of trial data. Going beyond that, either by treating men who don't need it or dosing above the therapeutic range, introduces risks not offset by clear benefits.
Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.
FAQs
Does TRT affect your life expectancy?
The TRAVERSE trial of 5,246 men found no increase in major cardiovascular events with testosterone gel over a mean 21.7 months in men with confirmed hypogonadism. A 2024 meta-analysis found severely low testosterone (below 213 ng/dL) was associated with higher all-cause mortality. The effect on life expectancy likely depends on baseline levels, dosing, and monitoring.
Is low testosterone dangerous if left untreated?
Severely low testosterone is associated with increased mortality risk. The Yeap et al. 2024 meta-analysis found men below 153 ng/dL had elevated cardiovascular mortality. Low levels also correlate with metabolic syndrome, increased visceral fat, and reduced bone density.
What did the TRAVERSE trial find about TRT and heart risk?
The trial randomized 5,246 men with hypogonadism and cardiovascular risk to testosterone gel or placebo. The primary endpoint (MACE) showed no increased risk (hazard ratio 0.96). The FDA removed its cardiovascular boxed warning in February 2025 and added a blood pressure monitoring requirement.
Can lifestyle changes replace TRT for low testosterone?
For men with borderline-low levels driven by obesity, poor sleep, or inactivity, yes. A 10% body weight reduction may raise testosterone by 80-100 ng/dL. These interventions don't work for primary hypogonadism, which typically requires medical treatment.
What monitoring is required during testosterone therapy?
The Endocrine Society recommends two pre-treatment morning testosterone draws, baseline PSA, hematocrit, and lipids. At three to six months: repeat trough testosterone, hematocrit, PSA, estradiol, and blood pressure. Hematocrit above 54% requires dose adjustment or phlebotomy.
References
More from Marek Health
Your biology has answers.
Custom labs, a dedicated care team, and treatment built on your biology, not guesswork. One program, built around you.
HIPAA compliant · We never sell your data